Physician profile
Jeffrey E Abrams
NPI 1679581011
$1,954.52
in general payments reported to CMS, 2019-2025
10 companies · $56.33 in 2025
The $56.33 reported for 2025 was less than what a typical Trauma Surgery provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.70 · 2021: $35.57 · 2022: $320 · 2023: $422 · 2024: $1,107 · 2025: $56.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984 · Travel and Lodging: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $983.95 |
| Travel and Lodging | $600.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $1,207.33 | 2023-2024 | Phasix Mesh |
| Boston Scientific Corporation | $212.80 | 2022-2025 | Spyglass Discover, Wavewriter Alpha Prime 16 |
| Intuitive Surgical, INC. | $198.32 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $148.22 | 2024 | Ribfix Blu Advantage |
| Baxter Healthcare | $50.00 | 2022 | |
| Medtronic, INC. | $35.57 | 2021 | |
| Haemonetics Corporation | $31.01 | 2025 | Teg6s Hemostasis System |
| Silk Road Medical, INC. | $29.16 | 2022 | |
| Abbott Laboratories | $24.70 | 2022 | |
| Organogenesis INC. | $17.41 | 2023 | Puraply |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.